K Watanabe et al. Clin Gastroenterol Hepatol 2018; 16: 542-9.
The DIAMOND study evaluated monotherapy with adalimumab (n=85) compared with combination therapy of adalimumab with azathioprine (n=91).
- In this subanalysis of patients with moderate and severe Crohn’s disease (CD), endoscopic response (defined by SES-CD drop of at least 8 points or SES-CD <4) was significantly higher at week 26: 71.6% vs 54.4%. The OR for endoscopic response was 2.12 at week 26 with combination therapy.
- At week 52 the endoscopic response difference was not statistically significant: 60% vs. 50%.
- Similarly, mucosal healing was more common (but not statistically significant) in the combination group compared with monotherapy: 20.9% vs 103% at week 26, and 21.5% vs 12.2% at week 52.
- While not statistically significant, the combination group had ADA trough that was higher (7.6 compared with 6.5).
My take: The results described above for endoscopic responses and mucosal healing rates are depicted in figure 2 (I do not have a digital copy of figure or permission to use). After one looks at this figure, depicting the data noted above, there certainly appears to be an advantage for the use of combination therapy in patients with moderate-to-severe CD.
Related blog posts:
- Combination Therapy with Adalimumab: Is It Helpful?
- ‘Don’t Believe Our Study’
- Should All Pediatric Patients with Crohn’s Disease Continue …
- Don’t be Fooled About Withdrawing Immunomodulator …
- Digging into the COMMIT Study | gutsandgrowth